Screener
Ionis Pharmaceuticals IONS Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Ionis Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
FAQ
- What is Ionis Pharmaceuticals's return on equity?
- Ionis Pharmaceuticals (IONS) reported return on equity of -105.5% in Q2 2026.
- How has Ionis Pharmaceuticals's return on equity changed year-over-year?
- Ionis Pharmaceuticals's return on equity decreased by 76.1% year-over-year, from -59.9% to -105.5%.
- What is the long-term trend for Ionis Pharmaceuticals's return on equity?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's return on equity has grown at a 12.7% compound annual growth rate (CAGR), from -39% to -70.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Ionis Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude